University Hospitals Brain Health & Memory Center is now treating patients with KISUNLA™ (donanemab), a Food and Drug Administration-approved medication for the treatment of Alzheimer’s disease. UH is ...

Peter Almond, 78, is compiling his memoirs. A retired journalist, he writes in the conservatory at his family home in Esher, ...

A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were not given the opportunity to know whether they carried APOE4, a genetic ...

An experimental nasal spray has helped clear toxic protein buildups in the brains of mouse models of Alzheimer's. Its ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

For the last eight years, Lakeland resident Natalie Aviles has participated in Walk to End Alzheimer’s Polk County. Each year ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...